Abbreviations: cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase 2; EGR-1, early growth response gene-1; EP4, prostaglandin E receptor 4; FBS, fetal bovine serum; IBMX, 1-methyl-3-isobutylxanthine; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFNγ, interferon γ; IL2, interleukin 2; MIP1α, macrophage inflammatory protein 1α; NK, natural killer; N-NK, NK from normal mice; NSCLC, non-small cell lung carcinoma; PGE 2 , prostaglandin E 2 ; PI3K, phosphoinositide-3-kinase; SDF1α, stromal cell derived factor 1α; T-NK, NK from tumor-bearing mice RQ-15986, CJ-042794). 10 In clinical trials, the RQ-15986-related compound RQ-07 has been shown to be safe and efficient against osteoarthritis-associated pain (unpublished observations) and is the only known EP4 antagonist available for clinical evaluation. The effects of RQ-15986 on innate immunity have not yet been investigated nor has its ability to inhibit tumor metastasis been determined. We now report that RQ-15986 restores the profound suppression of NK-cell functions that characterizes progressive tumor growth, an effect that is accompanied by marked antitumor and antimetastasis activity. These studies identify a potential new approach to prevent tumor-associated NK-cell suppression.
Introduction
The cyclooxygenase-2 (COX-2) product prostaglandin E 2 (PGE 2 ) mediates tumor-associated immunosuppression. Natural killer (NK) cells, which play a critical role in the control of metastases, are inhibited by PGE 2 acting on the cognate receptors EP2 and EP4. 1, 2 Previous studies from us and other laboratories support a key role for EP4 in promoting breast cancer metastasis, [3] [4] [5] [6] [7] [8] [9] but until now there have been few effective EP4 antagonists available for preclinical and clinical investigations. Here, we describe a novel orally active EP4 antagonist, RQ-00015986 (hereafter abbreviated cyclooxygenase-2 is frequently upregulated in epithelial tumors and contributes to poor outcomes in multiple malignancies. The cOX-2 product prostaglandin e 2 (pGe 2 ) promotes tumor growth and metastasis by acting on a family of four G protein-coupled receptors (ep1-4). Using a novel small molecule ep4 antagonist (RQ-15986) and a syngeneic murine model of metastatic breast cancer, we determined the effect of ep4 blockade on innate immunity and tumor biology. Natural killer (NK)-cell functions are markedly depressed in mice bearing murine mammary tumor 66.1 or 410.4 cells owing to the actions of pGe 2 on NK cell ep4 receptors. The ep4 agonist pGe 1 -Oh inhibits NK functions in vitro, and this negative regulation is blocked by RQ-15986. Likewise, the treatment of tumor-bearing mice with RQ-15986 completely protected NK cells from the immunosuppressive effects of the tumor microenvironment in vivo. RQ-15986 also has direct effects on ep4 expressed by tumor cells, inhibiting the pGe 2 -mediated activation of adenylate cyclase and blocking pGe 2 -induced tumor cell migration. The pretreatment of tumor cells with a non-cytotoxic concentration of RQ-15986 inhibited lung colonization, a beneficial effect that was lost in mice depleted of NK cells. The oral administration of RQ-15986 inhibited the growth of tumor cells implanted into mammary glands and their spontaneous metastatic colonization to the lungs, resulting in improved survival. Our findings reveal that ep4 antagonism prevents tumor-mediated NKcell immunosuppression and demonstrates the anti-metastatic activity of a novel ep4 antagonist. These observations support the investigation of ep4 antagonists in clinical trials.
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE 2 10 In clinical trials, the RQ-15986-related compound RQ-07 has been shown to be safe and efficient against osteoarthritis-associated pain (unpublished observations) and is the only known EP4 antagonist available for clinical evaluation. The effects of RQ-15986 on innate immunity have not yet been investigated nor has its ability to inhibit tumor metastasis been determined. We now report that RQ-15986 restores the profound suppression of NK-cell functions that characterizes progressive tumor growth, an effect that is accompanied by marked antitumor and antimetastasis activity. These studies identify a potential new approach to prevent tumor-associated NK-cell suppression.
ability of RQ-15986 to inhibit PGE 2 -mediated adenylate cyclase activation was confirmed using 410.4 mammary tumor cells (Fig. 1C) . In these cells, PGE 2 and PGE 1 -OH induced a 1.8-and 1.6-fold increase in cAMP levels, respectively. Both responses were inhibited by RQ-15986. Thus, like AH23848, RQ-15986 effectively antagonizes EP4 in mammary tumor cells.
We then determined the effect of RQ-15986 on mammary tumor cell growth. To this aim, 66.1 cells were cultured in the presence of 0.5-10 μM RQ-15986 or vehicle and cell number was determined at 24 and 48 h. RQ-15986 did not affect the growth of tumor cells in vitro (Fig. 1D) . Likewise, the proliferation of 410.4 cells was not altered in the presence of RQ-15986 (data not shown).
RQ-15986 inhibits tumor growth and metastasis in vivo. The ability of malignant cells to migrate across an artificial membrane
Results
A novel non-cytotoxic inhibitor of EP4. RaQualia Pharma has developed several high-affinity and highly selective EP4 antagonists. 10 RQ-15986 (Fig. 1A) potently inhibits PGE 2 -induced elevations in cAMP activity in HEK293 cells expressing murine EP4 (pA 2 value of 8.7). In malignant cells derived from the mammary gland, EP4 is similarly coupled to adenylate cyclase activation. 6 We examined the ability of RQ-15986 to inhibit this response in malignant cells exposed to PGE 2 or the EP4-specific agonist PGE 1 -OH (Fig. 1B) . Stimulation of murine 66.1 mammary tumor cells with 5 μM PGE 2 or PGE 1 -OH for 15 min resulted in a 2.1-or 2-fold elevation in intracellular cAMP, respectively. These responses were significantly inhibited by the EP4 antagonists AH23848 or RQ-15986 in a dose dependent manner. The interferon γ (IFNγ) levels by ELISA. The ability of NK cells to produce IFNγ upon IL-2 stimulation was completely suppressed in the presence of PGE 1 -OH (Fig. 3A) . RQ-15986 was able to completely protect NK cells from the immunosuppressive effects of PGE 1 -OH, restoring IFNγ production to the levels observed in control NK cells. We also determined the effect of PGE 2 on NK-cell migration. The ability of NK cells to migrate in response to fetal bovine serum (FBS) was depressed in the presence of PGE 1 -OH, an inhibitory effect that was prevented by EP4 antagonism with RQ-15986 (Fig. 3B) .
We then determined if RQ-15986 might protect NK cells from the functional inhibition that occurs in tumor-bearing mice. To this aim, we compared the functional activity of NK cells isolated from normal mice (N-NK cells) or 66.1 cell-derived tumorbearing mice (T-NK cells) that either received vehicle or 100 mg/ Kg RQ-15986 twice a day for 21 d. The ability of T-NK cells obtained from vehicle-treated mice to produce IFNγ was nearly absent as compared with that of N-NK cells (Fig. 4A) , indicating a profound suppression of NK cells by the tumor environment. Notably, RQ-15986 was able to reverse such a tumor-associated immune dysfunction. T-NK cells from RQ-15986-treated mice indeed produced IFNγ levels that were comparable to those generated by N-NK cells. Along similar lines, T-NK cells from vehicle-treated mice migrated poorly in response to FBS as well as upon chemotactic stimulation with the chemokines macrophage inflammatory protein 1α (MIP1α) and stromal cell derived factor 1α (SDF1α), compared with N-NK cells (Fig. 4B) . The administration of RQ-15986 to tumor-bearing mice rescued T-NK cells from this inhibition.
Discussion
The suppression of NK-cell functions in patients with breast cancer is partially attributable to PGE 2 , which is generated in large amounts by the elevated activity of COX-2 that is common to many epithelial tumors.
11 PGE 2 directly inhibits NK-cell functions primarily by binding EP4 receptors expressed on their surface. 1, 2 The results of clinical trials testing COX-2 inhibitors in cancer patients have been disappointing. The recent literature supports a potential benefit for targeting the COX-2 signaling pathway further downstream, at the level of individual EP receptors. However this branch of research has been hampered by the absence of clinically relevant EP4 antagonists. RQ-15986 is one of several high-affinity EP4 antagonists recently developed by RaQualia Pharma, Inc. 10 The RQ-15986-related compound RQ-07 has been investigated in four Phase I studies in healthy subjects and two Phase IIa trials in patients with osteoarthritisassociated pain and found to be safe and effective (unpublished observations). RQ-15986 has been shown to inhibit primary tumorigenesis in a model of inflammatory gastric cancer, 12 but the ability of this compound to modulate NK-cell functions and to inhibit tumor metastasis had not yet been investigated. Our findings provide support for the evaluation of the antineoplastic activity of novel EP4 antagonists in clinical trials.
Like many epithelial cancer cells, the mammary tumor cells used in this study produce significant levels of PGE 2 , both in vitro and in in a modified Boyden chamber is a surrogate measure of metastasis. PGE 2 and PGE 1 -OH induced the migration of mammary tumor cells by 2.2-and 1.9-fold, respectively ( Fig. 2A) . RQ-15986 was able to completely reverse PGE 2 or PGE 1 -OH-induced tumor cell migration. Based on these encouraging results, we determined the ability of RQ-15986 to inhibit lung colonization by tumor cells in vivo. To this aim, 66.1 tumor cells were incubated with 3 μM RQ-15986 or vehicle for 15 min, washed and intravenously injected into syngenic BALB/cByJ female mice. Twentyone days later, mice were euthanized and visceral metastases were enumerated. Mice injected with vehicle-treated tumor cells had an average of 49.6 ± 5 tumor colonies in the lungs, which were significantly less in mice injected with RQ-15986-treated tumor cells (Fig. 2B, 15 .2 ± 5, p < 0.003). Three of ten mice injected with vehicle-treated tumor cells also had grossly detectable tumor colonies on the heart, but 0/10 mice injected with RQ-15986-treated cells displayed cardiac metastases.
NK cells play an important role in controlling tumor dissemination. Vehicle-treated mammary tumor cells injected in BALB/cByJ mice depleted of NK cells produced more lung colonies (214 ± 8) than the same cells injected in control mice (Fig. 2B) , consistent with a protective role of endogenous NK cells. RQ-15986 was no longer able to limit the number of lung lesions (221.6 ± 9) in NK-depleted mice, indicating a critical role for NK cells in the mechanism by which EP4 antagonists inhibit metastasis. Sixty and 40% of NK-depleted mice displayed cardiac metastases after the injection of vehicle-treated vs. RQ-15986-treated tumor cells, respectively (data not shown).
To assess the effect of EP4 antagonism on tumor growth and spontaneous metastasis, 5 × 10 5 66.1 tumor cells were implanted proximal to the mammary gland of BALB/cByJ mice. Beginning on the next day, mice were treated twice a day with 100 mg/Kg RQ-15986 or vehicle for 21 d. Tumor volume was determined by caliper measurement and mice were euthanized when primary tumors achieved an average diameter of 18 mm, followed by the quantification of visceral metastases. Daily treatment with RQ-15986 resulted in an approximate 50% reduction in tumor volume (Fig. 2C , which was significantly lower starting after day 21). Spontaneous metastases to the lungs were reduced by 44% (Fig. 2D, 10 .7 ± 2.5 vs. 19.2 ± 1.9, p = 0.01). Time to euthanasia (tumor > 18 mm) was also significantly extended by treatment with the EP4 antagonist (Fig. 2E, p = 0.0003) .
RQ-15986 rescues NK cells from immunosuppression.
We have shown that NK cells are critical for the control of tumor dissemination (Fig. 2B and ref. 8 ) but NK-cell functions are profoundly suppressed in advanced malignancy. We assessed the capacity of RQ-15986 to rescue NK cells from PGE 2 -mediated immunosuppression. We first isolated NK-cell enriched populations from the spleens of normal BALB/cByJ mice by magnetic bead separation of DX5 + CD3 − cells, and examined the ability of RQ-15986 to protect NK-cell functions (migration, cytokine production) from PGE 2 -mediated inhibition. NK cells were pretreated with either vehicle or PGE 1 -OH for 30 min in the absence or presence of 3 μM RQ-15986. Then, NK cells were stimulated with 1,000 U/mL interleukin-2 (IL-2) for 18 h, after which conditioned culture media were harvested and assayed for COX-2 activity of mammary tumor cells, other cells in the tumor microenvironment including fibroblasts and myeloid cells can contribute to the increased production of PGE 2 . 14, 15 Experiments in which tumor cells were pre-treated with an EP4 antagonist point to a direct role for EP4 expression in the cell-intrinsic properties vivo. In our previous studies, we found cultured 66.1 cells to secrete 19.7 ± 3.4 ng/10 6 cells PGE 2 in 48 h, while 410.4 cells released 18.2 ± 1.9 ng/10 6 cells PGE 2 . 13 In 66.1 and 410.4-cell derived tumor homogenates, PGE 2 was quantified as 337 ± 70 and 321 ± 45 ng/g wet weight of tissue, respectively. In addition to the intrinsic NK-cell functions are profoundly inhibited in patients with advanced malignancies and in mammary tumor-bearing mice. Here, we have shown that the treatment of these mice with RQ-15986 leads to a nearly complete rescue of NK-cell functions. This is quite interesting because other non-prostaglandin tumor products also inhibit NK cells in vitro. 16 For example, COX-2 upregulates indoleamine-pyrrole 2,3-dioxygenase (IDO), a potent immunosuppressive mediator, 17, 18 implying that that contribute to their metastatic potential. Our previous findings also suggest that NK-mediated tumor cell lysis is enhanced in the presence of EP4 antagonists, a phenomenon that is mechanistically linked to a reduced expression of NK-inhibitory MHC Class I molecules. 8 Thus, EP4 antagonists inhibit tumor metastasis by multiple mechanisms, including reduced tumor cell migration, increased sensitivity to NK-mediated lysis and systemic protection of NK cells from PGE 2 -mediated immunosuppression. + cD3 − cell population were treated with DMsO, 5 μM pGe 1 -Oh and/or 3 μM RQ-15986 for 30 min followed by treatment with 1000 U/mL interleukin-2 (IL-2) for 18 h. conditioned media were then assayed for interferon γ (IFNγ) levels by eLIsa, in triplicate replicates. (B) NK cells were treated with 1 μM pGe 1 -Oh for 10 min and allowed to migrate across the top of a microplate (3 μm pore size) for 3 h in response to fetal bovine serum (FBs).
cancer and an EP4 antagonist inhibits growth in two xenograft models of castration-resistant disease.
27 EP4 positively regulates the expression of aromatase, leading to estrogen synthesis and reduces the expression of BRCA1 in breast cancer. 28 In addition to affecting tumor cell proliferation, EP4 plays a key role in promoting tumor cell dissemination in breast, lung and colon cancer. 6, 7, 19, 29, 30 Both the pharmacologic antagonism of EP4 and EP4 gene silencing inhibits tumor cell invasion, migration and metastasis in preclinical models of invasive ductal carcinoma and inflammatory breast cancer. [3] [4] [5] [6] Thus, EP4 is a relevant target in multiple histologically diverse neoplasms.
Many of these studies, including our own, were performed using a commercially available EP4 antagonist, AH23848, a compound that is not compatible with clinical development. Here, we provide for the first time evidence that a novel family of compounds, developed by RaQualia Pharma may constitute effective EP4 antagonists in cancer. We employed RQ-15986 because it exhibits an excellent pharmacological profile in rodents. RQ-07, a similar compound, has been shown to be safe and efficient against osteoarthritisassociated pain in clinical trials. To our knowledge, RQ-07 is the only EP4 antagonist that is ready for evaluation as an antineoplastic agent in clinical trials.
The current study demonstrates that RQ-15986 is able to markedly inhibit breast cancer metastasis, likely due to both the protective effect of EP4 antagonism on critical NK-cell functions as well as direct effects on tumor cells. These findings add to the growing literature supporting a key role for EP4 in promoting tumor metastasis and provide a potentially novel approach to prevent cancer-associated immunosuppression. Our results support the further examination of EP4 as a new therapeutic target in multiple malignancies.
Materials and Methods
Cells. Highly tumorigenic and metastatic 66.1 and 410.4 cells were derived from a spontaneously occurring mammary adenocarcinoma in a BALB/cfC3H mouse. Cells were maintained as previously described. Mice. BALB/cByJ female mice (Jackson Laboratory, 001026) were housed, cared for and used in strict accordance with the the COX-2/EP4 blockade may operate upstream of several other immunosuppressive mechanisms. These data are consistent with our finding demonstrating that neither RQ-15986, nor other EP4 antagonists nor an EP4-targeting short-hairpin RNA (shRNA) inhibit metastasis in the absence of NK cells. 8, 9 A consensus is growing on the notion that EP4 promotes multiple cancers of diverse histological origin.
19 EP4 is upregulated in colon adenomas/adenocarcinomas and promotes anchorage-independent growth and apoptosis resistance by a cAMP-dependent mechanism. 20, 21 Loss of miR-101 in colon cancer may explain the increased EP4 expression in this disease. 22 The EP4/CREBmediated activation of ERK leads to downstream expression of early growth response gene-1 (EGR-1), which supports the proliferation of colon cancer cells. 23 In T-cell leukemia, EP4 promotes apoptosis resistance through a phosphoinositide-3-kinase (PI3K)/ AKT pathway. 24 PGE 2 acting on the EP4 receptor induces nonsmall cell lung carcinoma (NSCLC) cell growth through increased expression of an integrin-linked kinase. 25 Angiogenesis in prostate cancer is induced by PGE 2 acting on EP2 and EP4 receptors.
26
EP4 is upregulated in castration-resistant hormone-naïve prostate cAMP assays. Cells were pretreated with 1 μM indomethacin for 24 h and transferred to complete cell culture medium containing 100 μM IBMX (Sigma Chemical Co., 17018). Agonists or antagonists were added to cells and incubated for 15 min. Intracellular cAMP levels were determined using either the Amersham cAMP Biotrak EIA kit (Fig. 1B) or the the cAMP EIA system (Cayman Chemicals, 581-001) (Fig. 1C) . Software provided with the latter kit allowed for the conversion of binding data to pM cAMP.
